Autres langues Telix Pharmaceuticals Limited

Actions

TLX

AU000000TLX2

Recherche biotechnologique et médicale

Temps Différé Australian S.E. 07:24:15 21/09/2026			Varia. 5j.	Varia. 1 janv.
16,40 ^AUD	-8,12%		+0,73%	+46,96%

15/09	Telix Pharmaceuticals Limited : Jarden Research maintient sa recommandation à l'achat	ZM
15/09	Les prévisions de BPA de Telix augmentent d'environ 9% pour l'exercice 2027 et de 21% pour l'exercice 2028 après l'approbation d'un traitement contre le gliome, selon Jefferies	MT

Autres langues

07:17	MÄRKTE ASIEN/Aktien freundlich - Ruhetag in Tokio - Ölpreis fällt weiter
06:43	MÄTKTE ASIEN/Aktien freundlich - Ruhetag in Tokio - Ölpreis fällt weiter
03:21	Telix Pharmaceuticals to Acquire German Radiopharmaceutical Biotechnology Company for Initial $1.65 Billion Payment, Shares Fall 3%
03:15	Australian shares edge lower as banks and miners drag
02:56	Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
00:56	Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
15/09	Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says
15/09	Telix Pharmaceuticals' US FDA Approval for Brain Cancer Imaging Agent to Help Diversify Revenue Stream, Jarden Says
14/09	Telix Pharmaceuticals Limited Receives FDA Approval for Pixclara Brain Cancer Imaging Drug
14/09	Telix Pharmaceuticals Receives FDA Approval for Brain Cancer Imaging Drug Pixclara
14/09	Telix Pharmaceuticals Says US FDA Approves New Drug Application for Brain Cancer Imaging Drug
14/09	Telix Pharmaceuticals : FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
11/09	ASX Biggest Losers
09/09	Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
03/09	ASX Biggest Gainers
02/09	Telix Pharmaceuticals Completes Patient Enrollment for Phase 3 Study of Imaging Agents in Prostate Cancer
02/09	Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging
02/09	Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
02/09	Telix Pharmaceuticals Limited Completes Enrollment In Phase 3 BiPASS Study Of Illuccix And Gozellix For Prostate Cancer Imaging
01/09	Telix Pharmaceuticals Names David Gill as Chair
01/09	Telix Pharmaceuticals Limited Announces Chair of the Board Changes
01/09	Telix Pharmaceuticals Appoints Chair
01/09	Telix Appoints David Gill as Chair
20/08	Telix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2026
20/08	Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline